US4457907A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Composition and method for protecting a therapeutic drug
Assignee: Clear Lake Development Group
•
Filing: 1982-08-05
•
Granted: 1984-07-03
•
Expires: 2002-08-05
Abstract
Abstract A therapeutic composition comprising a therapeutic drug that can cause undesirable effects on the pre-intestinal phases when contacting these phases, and an enteric coating surrounding the drug. A method for protecting a therapeutic drug including forming an enteric coating around the drug.
Inventors
- 👤 Garry L. Porter
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 05:28
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/28; A61K9/2806; A61K9/2833; A61K9/2853
Claims Analysis
Total Claims: 58
Claim 1
Independent Claim
127 words
A therapeutic composition available for therapeutic action in the postgastric portion of the gastrointestinal tract of an animal or a human, wherein premature release of the composition in the pre-intestinal phases of the gastrointestinal tract can result in alteration of the composition or in undesirable effects on the pre-intestinal phases by the composition, comprising (a) a therapeutic drug that can cause undesirable effects on the pre-intestinal phases when contacting these phases; and (b) an enteric coating surrounding the therapeutic drug, said enteric coating is a polypeptide that is resistant to degradation in the gastric environment, and said coating has a thickness of from about 0.01 to about 1.0 mm, said polypeptide is selected from the group consisting of polyarginine, polylysine, or a mixture of polyarginine and polylysine.
Claim 2
Dependent Claim
127 words
A therapeutic composition available for therapeutic action in the postgastric portion of the gastrointestinal tract of an animal or a human, wherein premature release of the composition in the pre-intestinal phases of the gastrointestinal tract can result in alteration of the composition or in undesirable effects on the pre-intestinal phases by the composition, comprising (a) a therapeutic drug that can cause undesirable effects on the pre-intestinal phases when contacting these phases; and (b) an enteric coating surrounding the therapeutic drug, said enteric coating is a polypeptide that is resistant to degradation in the gastric environment, and said coating has a thickness of from about 0.01 to about 1.0 mm, said polypeptide is selected from the group consisting of polyarginine, polylysine, or a mixture of polyarginine and polylysine.
Claim 3
Dependent Claim
11 words
The composition of claim 1 wherein said therapeutic drug is aspirin.
Claim 4
Dependent Claim
12 words
The composition of claim 1 wherein said therapeutic drug is a vitamin.
Claim 5
Dependent Claim
13 words
The composition of claim 1 wherein said therapeutic drug is a psychotropic medication.
Claim 6
Dependent Claim
13 words
The composition of claim 1 wherein said therapeutic drug is an anti-hypertensitive medication.
Claim 7
Dependent Claim
13 words
The composition of claim 1 wherein said therapeutic drug is an anti-seizure medication.
Claim 8
Dependent Claim
13 words
The composition of claim 1 wherein said therapeutic drug is an amphetamine medication.
Claim 9
Dependent Claim
13 words
The composition of claim 1 wherein said therapeutic drug is an anti-microbial medication.
Claim 10
Dependent Claim
13 words
The composition of claim 1 wherein said therapeutic drug is an antibiotic medication.
Claim 11
Dependent Claim
13 words
The composition of claim 1 wherein said therapeutic drug is an anti-fungal medication.
Claim 12
Dependent Claim
13 words
The composition of claim 1 wherein said therapeutic drug is an anti-depressant medication.
Claim 13
Dependent Claim
13 words
The composition of claim 1 wherein said therapeutic drug is a stimulant medication.
Claim 14
Dependent Claim
13 words
The composition of claim 1 wherein said therapeutic drug is an antihistamine medication.
Claim 15
Dependent Claim
13 words
The composition of claim 1 wherein said therapeutic drug is an antiallergy medication.
Claim 16
Dependent Claim
13 words
The composition of claim 1 wherein said therapeutic drug is a phenothiazine medication.
Claim 17
Dependent Claim
13 words
The composition of claim 1 wherein said therapeutic drug is an amine medication.
Claim 18
Dependent Claim
15 words
The composition of claim 1 wherein said therapeutic drug is a monoamine oxidase inhibitor medication.
Claim 19
Dependent Claim
13 words
The composition of claim 1 wherein said therapeutic drug is an anticarcinogen medication.
Claim 20
Dependent Claim
13 words
The composition of claim 1 wherein said therapeutic drug is an analgesic medication.
Claim 21
Dependent Claim
14 words
The composition of claim 1 wherein said therapeutic drug is a muscle relaxant medication.
Claim 22
Dependent Claim
14 words
The composition of claim 1 wherein said therapeutic drug is an ergot preparation medication.
Claim 23
Dependent Claim
13 words
The composition of claim 1 wherein said therapeutic drug is an anticholinergic medication.
Claim 24
Dependent Claim
13 words
The composition of claim 1 wherein said therapeutic drug is an antiinflammatory medication.
Claim 25
Dependent Claim
14 words
The composition of claim 1 wherein said therapeutic drug is an antigout preparation medication.
Claim 26
Dependent Claim
13 words
The composition of claim 1 wherein said therapeutic drug is a soporfic medication.
Claim 27
Dependent Claim
14 words
The composition of claim 1 wherein said therapeutic drug is a hormonal preparation medication.
Claim 28
Dependent Claim
14 words
The composition of claim 1 wherein said therapeutic drug is an appetite suppressant medication.
Claim 29
Independent Claim
117 words
A method for protecting a therapeutic drug from the effects of an oral, esophageal, and/or gastric environment found in an animal or human and then making the drug available in the postgastric portion of the gastro-intestinal tract, comprising the steps of: forming an enteric coating around the drug, said coating being resistant to the gastric and pre-gastric environments and being subject to chemical and/or enzymatical action in the postgastric environment, said forming of an enteric coating is with a polypeptide which is resistant to gastric and pregastric environment and selected from the group consisting of polyarginine, polylysine, or a mixture of polyarginine and polylysine, said coating having a thickness of from about 0.01 to about 1.0 mm.
Claim 30
Independent Claim
117 words
A method for protecting a therapeutic drug from the effects of an oral, esophageal, and/or gastric environment found in an animal or human and then making the drug available in the postgastric portion of the gastro-intestinal tract, comprising the steps of: forming an enteric coating around the drug, said coating being resistant to the gastric and pre-gastric environments and being subject to chemical and/or enzymatical action in the postgastric environment, said forming of an enteric coating is with a polypeptide which is resistant to gastric and pregastric environment and selected from the group consisting of polyarginine, polylysine, or a mixture of polyarginine and polylysine, said coating having a thickness of from about 0.01 to about 1.0 mm.
Claim 31
Dependent Claim
11 words
The method of claim 28 wherein said therapeutic drug is aspirin.
Claim 32
Dependent Claim
12 words
The method of claim 28 wherein said therapeutic drug is a vitamin.
Claim 33
Dependent Claim
13 words
The method of claim 28 wherein said therapeutic drrug is a psychotropic medication.
Claim 34
Dependent Claim
13 words
The method of claim 28 wherein said therapeutic drug is an anti-hypertensitive medication.
Claim 35
Dependent Claim
13 words
The method of claim 28 wherein said therapeutic drug is an anti-seizure medication.
Claim 36
Dependent Claim
13 words
The method of claim 28 wherein said therapeutic drug is an amphetamine medication.
Claim 37
Dependent Claim
13 words
The method of claim 28 wherein said therapeutic drug is an anti-microbial medication.
Claim 38
Dependent Claim
13 words
The method of claim 28 wherein said therapeutic drug is an antibiotic medication.
Claim 39
Dependent Claim
13 words
The method of claim 28 wherein said therapeutic drug is an anti-fungal medication.
Claim 40
Dependent Claim
13 words
The method of claim 28 wherein said therapeutic drug is an anti-depressant medication.
Claim 41
Dependent Claim
13 words
The method of claim 28 wherein said therapeutic drug is a stimulant medication.
Claim 42
Dependent Claim
13 words
The method of claim 28 wherein said therapeutic drug is an antihistamine medication.
Claim 43
Dependent Claim
13 words
The method of claim 28 wherein said therapeutic drug is an antiallergy medication.
Claim 44
Dependent Claim
13 words
The method of claim 28 wherein said therapeutic drug is a phenothrazine medication.
Claim 45
Dependent Claim
13 words
The method of claim 28 wherein said therapeutic drug is an amine medication.
Claim 46
Dependent Claim
15 words
The method of claim 28 wherein said therapeutic drug is a monoamine oxidase inhibitor medication.
Claim 47
Dependent Claim
13 words
The method of claim 28 wherein said therapeutic drug is an anticarcinogen medication.
Claim 48
Dependent Claim
13 words
The method of claim 28 wherein said therapeutic drug is an analgesic medication.
Claim 49
Dependent Claim
14 words
The method of claim 28 wherein said therapeutic drug is a muscle relaxant medication.
Claim 50
Dependent Claim
14 words
The method of claim 28 wherein said therapeutic drug is an ergot preparation medication.
Claim 51
Dependent Claim
13 words
The method of claim 28 wherein said therapeutic drug is an anticholinergic medication.
Claim 52
Dependent Claim
13 words
The method of claim 28 wherein said therapeutic drug is an antiinflammatory medication.
Claim 53
Dependent Claim
14 words
The method of claim 28 wherein said therapeutic drug is an antigout preparation medication.
Claim 54
Dependent Claim
13 words
The method of claim 28 wherein said therapeutic drug is a soporfic medication.
Claim 55
Dependent Claim
14 words
The method of claim 28 wherein said therapeutic drug is a hormonal preparation medication.
Claim 56
Dependent Claim
14 words
The method of claim 28 wherein said therapeutic drug is an appetite suppressant medication.
Claim 57
Dependent Claim
26 words
The composition of claim 1 wherein said enteric coating comprises a certain color for a certain thickness in order to readily ascertain the enteric coating thickness.
Claim 58
Dependent Claim
25 words
The method of claim 28 additionally comprising coloring each coating thickness a different color in order that the user can readily determine the coating thickness.
References Cited (Backward Citations)
US874310A
Cited
US1335488A
Cited
US2687367A
Cited
US2657972A
Cited
US2996431A
Cited
US2921001A
Cited
US2957804A
Cited
US3351531A
Cited
US3629390A
Cited
US3639565A
Cited
US3867520A
Cited
US4351337A
Cited
US4291016A
Cited
US4175119A
Cited
US4230687A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-07-03 | 1988-01-02 | 1988-07-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-07-03 | 1992-01-02 | 1992-07-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-07-03 | 1996-01-02 | 1996-07-03 | $7700.00 | Window Closed / Lapsed |